SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Founded in late 2016, we develop first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signalling pathways, including TNF-alpha signalling. Following the preclinical and early clinical development of these monoclonal antibodies, we are aiming to provide superior treatment options to currently existing inhibitors of TNF-alpha signaling. SciRhom is poised to transform the lives of patients with autoimmune diseases.
Location: Germany, Bavaria, Martinsried
Employees: 11-50
Total raised: $68.13M
Founded date: 2016
Investors 3
| Date | Name | Website |
| 10.07.2026 | Kurma Part... | kurmapartn... |
| 30.01.2025 | Andera Par... | anderapart... |
| 17.07.2021 | High-Tech ... | htgf.de |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.07.2024 | Series A | $68.13M | Andera Par... |
Mentions in press and media 7
| Date | Title | Description |
| 24.04.2026 | Kurma Partners: €215 Million Biofund IV Closes As Total AUM Reach €1 Billion | Kurma Partners, a Paris-based European healthcare venture capital firm and Eurazeo group company, has announced the final closing of Biofund IV at €215 million, bringing total assets under management across all Kurma Partners franchises to ... |
| 12.07.2024 | SciRhom's Groundbreaking Series A Financing | SciRhom, a Munich-based biopharmaceutical company, recently secured a whopping EUR 63 million in Series A funding. The round was co-led by top investors like Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Part... |
| 09.07.2024 | Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom | Andera Partners, a leading European private equity player, announced today that it is co-leading a € 63 million ($ 70 million) Series A financing for SciRhom, a biopharmaceutical company pioneering the development of first-in-class therapeu... |
| 09.07.2024 | SciRhom Raises EUR 63M in Series A Financing | SciRhom, a Munich, Germany-based biopharmaceutical company developing therapeutic iRhom2 antibodies, raised EUR 63M in Series A funding. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington P... |
| 09.07.2024 | SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases | The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy. Munich, Germany, July 9, 20... |
| 01.12.2021 | SciRhom augments seed financing to reach total funding of 16 million euros | The Martinsried-based company SciRhom was able to increase its seed capital to a total of EUR 16 million in another seed financing round. This support is expected to help reach the next development milestones of the novel antibody therapy a... |
| - | SciRhom | “Home - SciRhom GmbH” |